TTX Tetratherix Limited
Healthcare · Biotechnology
· website
· 25 employees
$6.45
52wk 3.09 – 8.08
Overall
63.8
Value
62.5
Growth
100.0
Health
66.3
Quality
0.0
Momentum
77.6
Dividend
—
Price
About Tetratherix Limited
Tetratherix Limited engages in biomaterial and regenerative medicine business in Australia and internationally. The company manufactures and commercialize medical devices in the areas of bone regeneration, tissue spacing, tissue regeneration, and precision medicine applications through its Tetramatrix platform technology. Tetratherix Limited was incorporated in 2015 and is based in Alexandria, Australia.
Price analytics
Returns
| 1 day | 1.1% |
| 1 week | 4.0% |
| 1 month | -8.6% |
| 3 months | 0.0% |
| 6 months | 50.0% |
| 1 year | 57.3% |
| 3 years | — |
Risk
| Volatility (1y ann.) | 64.5% |
| Beta vs ASX 200 | 0.75 |
| Sharpe (1y) | 0.96 |
| VaR 95% (1-day) | -5.7% |
| Max drawdown (1y) | -39.2% |
| Off 1-year high | -16.2% |
Technicals
| RSI(14) | 49 |
| vs 50DMA | -4.8% |
| vs 200DMA | 21.1% |
| Trend | Golden cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
62.5
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
0
Price / Sales
0
Growth
100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
66.3
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
92
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
77.6
6-month return vs ASX 200
100
Price vs 200-day average
100
Price vs 50-day average
26
Position in 52-week range
67
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$342.23M
P/E (trailing)
—
P/E (forward)
-49.74
EPS (trailing)
-0.18
Dividend yield
—
Payout ratio
0.0%
Beta
—
EV / EBITDA
-33.85
Price / Book
10.45
ROE
-31.1%
Operating margin
-194.5%
Net margin
-241.4%
Total cash
$34.36M
Total debt
$10.97M
Current ratio
4.50
Debt / Equity
0.34
Free cash flow
$-5.76M
Avg volume
24,566
Latest annual results
(FY ending 30 Jun 2026)
- Revenue$918.15K
- Gross profit$918.15K
- Operating income-$12.50M
- Net income-$9.32M
- Diluted EPS—
- Free cash flow-$7.93M
- Net debt-$23.40M